Exclusive-Evolent Health in sale talks after receiving takeover interest, sources say
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Truist Securities Reiterates Buy Rating on Evolent Health (EVH)
August 23, 2024 7:02 AM EDTTruist Securities analyst Jailendra Singh reiterated a Buy rating and $33.00 price target on Evolent Health (NYSE: EVH).
The analyst comments "Bottom Line. M&A discussions related to EVH, whether in part of whole, is not a foreign discussion to the company. However, we... More
Piper Sandler Reiterates Overweight Rating on Evolent Health (EVH)
August 22, 2024 3:59 PM EDTPiper Sandler analyst Jessica Tassan reiterated an Overweight rating and $38.00 price target on Evolent Health (NYSE: EVH).
The analyst comments "Reuters reports that EVH is weighing sale, following takeover interest. The publication states that EVH has received initial offers and that potential acquirers could include PE firms or ELV (not covered) in combination with a PE partner. Our thoughts on today's news. 1. EVH is defining and dominating the market for value-based specialty care management. This is a $732B TAM which we define our white paper on the space here. 2. EVH has assembled best-in-class... More
BTIG Reiterates Buy Rating on Evolent Health (EVH)
August 22, 2024 3:57 PM EDTBTIG analyst David Larsen reiterated a Buy rating and $45.00 price target on Evolent Health (NYSE: EVH)
The analyst comments "Shares of EVH are trading up due to an article in Reuters, stating that several private equity firms, and at least one large health plan, are in discussions to potentially acquire EVH. The press report highlights that a process started after EVH received in-bound... More
